drugset
drugset / Trial / NCT04525885

A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension

NCT04525885 ↗

Phase 3 Completed 161 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period. It is hypothesized that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at Week 24.

Timeline

Start
2019-05-17
Primary completion
2022-09-15
Completion
2022-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefapixant Small molecule 15 mg Oral
Subject Gefapixant Small molecule 45 mg Oral

Indications

No indication recorded.